SCHEMBL5364738

SCHEMBL5364738

O=C1c2cccc(N3CCNCC3)c2Oc2ccc(F)cc2N1Cc1cccc(Cl)c1

nearest known ligand 0.79

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 7/20 0.79
LMNA P02545 3/20 0.48
MAPT P10636 3/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
EGFR P00533 4/20 0.47
UBE2N P61088 2/20 0.44
TDP1 Q9NUW8 1/20 0.44
MEN1 O00255 1/20 0.41
CASP6 P55212 1/20 0.41
KMT2A Q03164 1/20 0.41
HPGD P15428 1/20 0.41
ATM Q13315 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
ALDH3A1 P30838 1/20 0.40
KDM4E B2RXH2 1/20 0.40
MAPK1 P28482 1/20 0.40
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5364868 0.93 HTR6 (0.69) HTR6LMNAMAPTSMN1; SMN2EGFR
SCHEMBL5364715 0.93 HTR6 (0.82) HTR6LMNAEGFRUBE2NTDP1
SCHEMBL5372213 0.93 HTR6 (0.68) HTR6LMNAMAPTSMN1; SMN2MEN1
SCHEMBL5360955 0.92 HTR6 (0.80) HTR6LMNAEGFRUBE2NTDP1
SCHEMBL5357019 0.90 HTR6 (0.64) HTR6LMNAMAPTSMN1; SMN2MEN1
SCHEMBL5368470 0.89 HTR6 (0.79) HTR6LMNAMAPTSMN1; SMN2EGFR
SCHEMBL5362910 0.89 HTR6 (1.00) HTR6LMNAMAPTSMN1; SMN2EGFR
SCHEMBL5361668 0.88 HTR6 (0.66) HTR6LMNAMAPTSMN1; SMN2EGFR
SCHEMBL5356074 0.86 HTR6 (0.59) HTR6LMNAMAPTSMN1; SMN2EGFR
SCHEMBL5366505 0.86 HTR6 (0.74) HTR6LMNAMAPTEGFRUBE2N

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7229984-B2 Dibenzoxazepinone derivatives and uses thereof ROCHE PALO ALTO LLC (US) 2007-06-12 US claimed
US-20060154914-A1 Dibenzoxazepinone derivatives and uses thereof ROCHE PALO ALTO LLC 2006-07-13 US claimed
US-7229984-B2 Dibenzoxazepinone derivatives and uses thereof ROCHE PALO ALTO LLC (US) 2007-06-12 US disclosed
US-7229984-B2 Dibenzoxazepinone derivatives and uses thereof ROCHE PALO ALTO LLC (US) 2007-06-12 US disclosed
US-7229984-B2 Dibenzoxazepinone derivatives and uses thereof ROCHE PALO ALTO LLC (US) 2007-06-12 US disclosed
US-20060154914-A1 Dibenzoxazepinone derivatives and uses thereof ROCHE PALO ALTO LLC 2006-07-13 US disclosed
WO-2006061126-A2 DIBENZOXAZEPINONE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2006-06-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060154914-A1 Dibenzoxazepinone derivatives and uses thereof HTR6, BDKRB1, HTR7 HTR6 1/4885LMNA 1520/4885MAPT 4738/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.